Eczema Resources
Midwest Allergy Sinus Asthma, SCEczema is the name for a group of common, noninfectious conditions that typically cause the skin to become red, itchy, and inflamed. While the exact cause of eczema is unknown, more than thirty million Americans have some kind of this condition.
There are multiple types of eczema that exist, such as:
– Atopic dermatitis
– Contact dermatitis
– Dyshidrotic eczema
– Nummular eczema
– Seborrheic dermatitis
– Stasis dermatitis
It is possible to have more than one type of eczema at once, although all types can cause itching and redness, but some may also cause blistering, “weeping,” and/or peeling of the skin.
If you suspect you have a form of eczema, consult your doctor or contact us at (309) 452-0995 or (217) 717-4404 to book an appointment at one of our clinics today.
Other resources:
Related Articles:
AD Study
If your child have atopic dermatitis and is between 6-7 years old, contact us to learn more about the study of an investigational cream.
Clinical Trial: Moderate to Severe Eczema/Atopic Dermatitis (Rocket-Horizon) – CLOSED
(Enrollment Closed) Are you 18 years old and above? Have you had moderate to severe Eczema/Atopic Dermatitis for at least three years? Have you tried Topical Corticosteroid over the past 12 months but it did not work? We accept participants of all sexes. You may be...
Clinical Trial: Call for Moderate-Severe Eczema Patients (SIGNAL-AD) – CLOSED
We are looking for people with moderate to severe eczema who are 18 years old or above to participate in a study. The patient will be paid while getting close care and monitoring by doctors you know.
Great News: Positive Top-Line Result for Safety and Efficacy of a Non-Steroidal Topical Treatment for Atopic Dermatitis in Children (MASA SWIA)
On July 11, 2023, MASA’s research team at Sneeze Wheeze and Itch Associates received great news regarding the positive top-line research results on the safety and efficacy of a non-steroidal topical treatment for Atopic Dermatitis (AD) in children. The SWIA research team, led by Dr. Siri as Principal Investigator, contributed to the pivotal Phase 3 study for ruxolitinib cream, along with 98 other research centers worldwide!
